{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:03:32Z","timestamp":1790463812385,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.revmed.2021.10.329","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:49:52Z","timestamp":1637128192000},"page":"160-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["H\u00e9patite Delta\u00a0: \u00e9pid\u00e9miologie, diagnostic, histoire naturelle et traitements"],"prefix":"10.1016","volume":"43","author":[{"given":"D.","family":"Loureiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Castelnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Bed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2021.10.329_bib0300","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2021.10.329_bib0305","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/liv.14357","article-title":"New epidemiology of hepatitis delta","volume":"40","author":"Vlachogiannakos","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2021.10.329_bib0310","unstructured":"WHO | Global hepatitis report, 2017. WHO n.d. http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/ [accessed October 30, 2020]."},{"key":"10.1016\/j.revmed.2021.10.329_bib0315","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2021.10.329_bib0320","unstructured":"Gordien E. L\u2019infection par le virus de l\u2019h\u00e9patite Delta. Donn\u00e9es fran\u00e7aise r\u00e9centes - Bulletin \u00e9pid\u00e9miologique hebdomadaire n.d. http:\/\/beh.santepubliquefrance.fr\/beh\/2015\/19-20\/2015_19-20_3.html [accessed January 7, 2021]."},{"key":"10.1016\/j.revmed.2021.10.329_bib0325","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0330","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development","volume":"73","author":"Tout","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0335","doi-asserted-by":"crossref","first-page":"e58340","DOI":"10.1371\/journal.pone.0058340","article-title":"Proteoglycans act as cellular hepatitis delta virus attachment receptors","volume":"8","author":"Lamas Longarela","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.revmed.2021.10.329_bib0340","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"ELife"},{"key":"10.1016\/j.revmed.2021.10.329_bib0345","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coviro.2018.04.004","article-title":"Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections","volume":"30","author":"Tu","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0350","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1128\/jvi.66.2.914-921.1992","article-title":"Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex","volume":"66","author":"Xia","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0355","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4161\/rna.8.2.14238","article-title":"Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: variations on a theme","volume":"8","author":"Flores","year":"2011","journal-title":"RNA Biol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0360","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2009.02.007","article-title":"The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III","volume":"386","author":"Greco-Stewart","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0365","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/26912","article-title":"Crystal structure of a hepatitis delta virus ribozyme","volume":"395","author":"Ferr\u00e9-D\u2019Amar\u00e9","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2021.10.329_bib0370","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1073\/pnas.97.1.424","article-title":"A host-specific function is required for ligation of a wide variety of ribozyme-processed RNAs","volume":"97","author":"Reid","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2021.10.329_bib0375","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.1073\/pnas.232416799","article-title":"Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1","volume":"99","author":"Wong","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2021.10.329_bib0380","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/380454a0","article-title":"RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase","volume":"380","author":"Polson","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2021.10.329_bib0385","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1128\/jvi.67.12.7659-7662.1993","article-title":"Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen","volume":"67","author":"Hwang","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0390","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1073\/pnas.88.19.8490","article-title":"The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus","volume":"88","author":"Chang","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.revmed.2021.10.329_bib0395","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/JVI.78.5.2537-2544.2004","article-title":"Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades","volume":"78","author":"Radjef","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0400","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3201\/eid1209.060112","article-title":"Eighth major clade for hepatitis delta virus","volume":"12","author":"Le Gal","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.revmed.2021.10.329_bib0405","series-title":"Hepat. Delta Virus","first-page":"151","article-title":"Hepatitis Delta virus genetic variability: from Genotypes I, II, III to eight major clades?","author":"D\u00e9ny","year":"2006"},{"key":"10.1016\/j.revmed.2021.10.329_bib0410","first-page":"857","article-title":"Detecting hepatitis B virus in surgical smoke emitted during laparoscopic surgery","volume":"73","author":"Kwak","year":"2016","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.revmed.2021.10.329_bib0415","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/liv.13556","article-title":"Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country","volume":"38","author":"Sellier","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2021.10.329_bib0420","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/liv.13604","article-title":"Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN)","volume":"38","author":"Wranke","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2021.10.329_bib0425","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.28772","article-title":"First international external quality assessment for hepatitis delta virus RNA quantification in plasma","volume":"64","author":"Le Gal","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0430","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0435","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0168-8278(87)80032-6","article-title":"Rapidly progressive HBsAg-positive hepatitis in Italy: The role of hepatitis delta virus infection","volume":"5","author":"Saracco","year":"1987","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0440","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.revmed.2021.10.329_bib0445","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.14838","article-title":"New therapies for hepatitis delta virus infection","volume":"41","author":"Loureiro","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2021.10.329_bib0450","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-5926-3-8","article-title":"Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C","volume":"23","author":"Poynard","year":"2004","journal-title":"Comp Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0455","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hep.20935","article-title":"A novel panel of blood markers to assess the degree of liver fibrosis","volume":"42","author":"Cal\u00e8s","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0460","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0465","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virusres.2018.03.013","article-title":"diagnostics:Utilization and testing in the United States","volume":"250","author":"Safaie","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.revmed.2021.10.329_bib0470","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.13834","article-title":"Noninvasive markers for staging fibrosis in chronic delta hepatitis","volume":"45","author":"Takyar","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2021.10.329_bib0475","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jnci\/djs168","article-title":"A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma","volume":"104","author":"Ji","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.revmed.2021.10.329_bib0480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/JCM.37.1.235-237.1999","article-title":"Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis","volume":"37","author":"Chu","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0485","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0490","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0495","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2021.10.329_bib0500","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0032-1323630","article-title":"Liver transplantation in delta virus infection","volume":"32","author":"Roche","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.revmed.2021.10.329_bib0505","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.transproceed.2016.02.076","article-title":"Hepatitis B Virus and Hepatitis D Virus recurrence in patients undergoing liver transplantation for Hepatitis B Virus and Hepatitis B Virus Plus Hepatitis D Virus","volume":"48","author":"Adil","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.revmed.2021.10.329_bib0510","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.transproceed.2019.01.163","article-title":"Recurrence of Hepatitis D virus in liver transplant recipients with Hepatitis B and D virus\u2013related chronic liver disease","volume":"51","author":"Serin","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.revmed.2021.10.329_bib0515","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0520","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0525","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2021.10.329_bib0530","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2\u00a0trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.revmed.2021.10.329_bib0535","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.revmed.2021.10.329_bib0540","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0545","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"Final results of a multicenter, open-label phase 2\u00a0clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0550","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.revmed.2021.10.329_bib0555","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1\u00a0study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0560","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30464-6","article-title":"A phase 2\u00a0study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis - end of study results from the LOWR HDV-3\u00a0study","volume":"66","author":"Koh","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0565","first-page":"121A","article-title":"A Phase 2\u00a0Study Of Titrating-Dose Lonafarnib Plus Ritonavir In Patients With Chronic Hepatitis D: Interim Results From The Lonafarnib With Ritonavir In HDV-4 (LOWR HDV-4) Study","volume":"64","author":"Wedemeyer","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2021.10.329_bib0570","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0168-8278(17)30327-6","article-title":"A phase 2\u00a0dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2\u00a0study","volume":"66","author":"Yurdaydin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0575","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S0618-8278(19)30058-1","article-title":"PS-052-End of study results from LIMT HDV study: 36\u00a0% durable virologic response at 24\u00a0weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection","volume":"70","author":"Etzion","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0580","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/S0168-8278(20)30774-1","article-title":"LBP13 - A Phase 2\u00a0Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24\u00a0Weeks: End-of-Treatment Results from the LIFT HDV Study","volume":"73","author":"Koh","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0585","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/S0168-8278(20)30774-1","article-title":"A phase 2\u00a0study of peginterferon lambda, lonafarnib, and ritonavir for 24\u00a0weeks: end-of-study results from the lift HDV study","volume":"73","author":"Koh","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.revmed.2021.10.329_bib0295","series-title":"Chronic hepatitis D virus infection: developing drugs for treatment guidance for industry. Draft Guidance","year":"2019"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866321010535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866321010535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:44:43Z","timestamp":1759337083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866321010535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0248866321010535"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2021.10.329","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"H\u00e9patite Delta\u00a0: \u00e9pid\u00e9miologie, diagnostic, histoire naturelle et traitements","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2021.10.329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}